131 related articles for article (PubMed ID: 37909307)
21. Baricitinib (Olumiant) for the Treatment of Alopecia Areata.
Pheasant L
Am Fam Physician; 2023 Nov; 108(5):513-514. PubMed ID: 37983706
[No Abstract] [Full Text] [Related]
22. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
Jabbari A; Dai Z; Xing L; Cerise JE; Ramot Y; Berkun Y; Sanchez GA; Goldbach-Mansky R; Christiano AM; Clynes R; Zlotogorski A
EBioMedicine; 2015 Apr; 2(4):351-5. PubMed ID: 26137574
[TBL] [Abstract][Full Text] [Related]
23. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Fetter T; Rios GC; Niebel D; Bieber T; Wenzel J
Acta Derm Venereol; 2020 May; 100(10):adv00144. PubMed ID: 32285135
[TBL] [Abstract][Full Text] [Related]
24. Baricitinib (Olumiant) for severe alopecia areata.
Med Lett Drugs Ther; 2022 Sep; 64(1658):139-141. PubMed ID: 36094552
[No Abstract] [Full Text] [Related]
25. The Good and Bad News About New Drugs for Treating Alopecia Areata.
Morgado-Carrasco D; Rodríguez-Lobato E; Riera-Monroig J; Ferrando J
Actas Dermosifiliogr (Engl Ed); 2018; 109(1):69-70. PubMed ID: 28641742
[No Abstract] [Full Text] [Related]
26. Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata.
Chen D; Huang W; Zhongjie W; Feifeng R; Luo L; Jun Z; Dongmei H; Tian M; Tang L
Rheumatology (Oxford); 2022 Aug; 61(8):e221-e223. PubMed ID: 35148369
[No Abstract] [Full Text] [Related]
27. What's New in Hair Loss.
Santos LDN; Shapiro J
Dermatol Clin; 2019 Apr; 37(2):137-141. PubMed ID: 30850035
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience.
Gargiulo L; Ibba L; Vignoli CA; Ferrucci SM; Mercuri SR; Malagoli P; Marzano AV; Barbareschi M; Bianchi VG; Valenti M; Costanzo A; Narcisi A
J Dermatolog Treat; 2023 Dec; 34(1):2268764. PubMed ID: 37818648
[No Abstract] [Full Text] [Related]
29. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis.
Delvino P; Bartoletti A; Monti S; Biglia A; Montecucco C; Carducci M; Ripamonti G; Cavagna L
Rheumatology (Oxford); 2020 Dec; 59(12):e125-e127. PubMed ID: 32353871
[No Abstract] [Full Text] [Related]
30. Baricitinib for alopecia areata.
Imran H; Hoda F; Shakil F
J Pak Med Assoc; 2023 May; 73(5):1172. PubMed ID: 37218276
[No Abstract] [Full Text] [Related]
31. Comment on ‘Treatment of moderate-to-severe alopecia areata in preadolescent children with baricitinib’: authors’ reply.
Asfour L; Bokhari L; Bhoyrul B; Eisman S; Moussa A; Rees H; Sinclair RD
Br J Dermatol; 2023 Dec; 190(1):136-137. PubMed ID: 37596774
[No Abstract] [Full Text] [Related]
32. Baricitinib: A chance to treat COVID-19?
Lo Caputo S; Corso G; Clerici M; Santantonio TA
J Med Virol; 2020 Nov; 92(11):2343-2344. PubMed ID: 32437019
[No Abstract] [Full Text] [Related]
33. Alopecia areata: Line-field confocal optical coherence tomography features and dermoscopy correlation.
Lacarrubba F; Verzì AE; Dall'Oglio F; Villani A; Micali G
Skin Res Technol; 2024 Mar; 30(3):e13596. PubMed ID: 38419405
[No Abstract] [Full Text] [Related]
34. Ruxolitinib for the treatment of severe alopecia areata.
Liu LY; King BA
J Am Acad Dermatol; 2019 Feb; 80(2):566-568. PubMed ID: 30195572
[No Abstract] [Full Text] [Related]
35. Monitoring Response to Platelet-Rich Plasma in Patients with Alopecia Areata with Optical Coherence Tomography: A Case Series.
Ekelem C; Juhasz M; Yu J; Hosking AM; Csuka E; Choi F; Pham CT; Heidari AE; Valdebran M; Rapaport JA; Chen Z; Mesinkovska NA
J Investig Dermatol Symp Proc; 2020 Nov; 20(1):S50-S54. PubMed ID: 33099385
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Progression of Acrodermatitis Continua of Hallopeau With Baricitinib.
Han GM; Yang WS; Yang B
JAMA Dermatol; 2021 Apr; 157(4):466-468. PubMed ID: 33656520
[No Abstract] [Full Text] [Related]
37. Case reports: alopecia universalis: hair growth following initiation of simvastatin and ezetimibe therapy.
Robins DN
J Drugs Dermatol; 2007 Sep; 6(9):946-7. PubMed ID: 17941369
[TBL] [Abstract][Full Text] [Related]
38. Comment on 'Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children'.
Buontempo MG; Sicco KL; Shapiro J
Br J Dermatol; 2023 Dec; 190(1):135. PubMed ID: 37681491
[No Abstract] [Full Text] [Related]
39. Successful treatment of spondyloenchondrodysplasia with baricitinib.
Shimizu M; Inoue N; Mizuta M; Irabu H; Okajima M; Honda Y; Nihira H; Izawa K; Yachie A; Wada T
Rheumatology (Oxford); 2021 Feb; 60(2):e44-e46. PubMed ID: 32856090
[No Abstract] [Full Text] [Related]
40. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
